Biomarkers for the diagnosis and management of Parkinson's disease

Bibliography

• Mizuno Y, Hattori N, Kubo S, Progress in the pathogenesis and genetics of Parkinson's disease. Philos Trans R Soc Lond B Biol Sci 2008;363:2215-27
   PubMed Web of Science ®Google Scholar
• Jankovic J. Parkinson's disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry 2008;79:368-76
   PubMed Web of Science ®Google Scholar
• Tolosa E, Gaig C, Santamaria J, Compta Y. Diagnosis and the premotor phase of Parkinson disease. Neurology 2009;72(7 Suppl):S12-20
   PubMedGoogle Scholar
• Hughes AJ, Daniel SE, Ben-Shlomo Y, The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 2002;125:861-70
   PubMed Web of Science ®Google Scholar
• Greffard S, Verny M, Bonnet AM, Motor score of the Unified Parkinson disease rating scale as a good predictor of Lewy body-associated neuronal loss in the substantia nigra. Arch Neurol 2006;63:584-8
   PubMed Web of Science ®Google Scholar
• Hilker R, Schweitzer K, Coburger S, Nonlinear progression of Parkinson disease as determined by serial positron emission tomographic imaging of striatal fluorodopa F 18 activity. Arch Neurol 2005;62:378-82
   PubMed Web of Science ®Google Scholar
• Marek K, Jennings D, Tamagnan G, Seibyl J. Biomarkers for Parkinson's [corrected] disease: tools to assess Parkinson's disease onset and progression. Ann Neurol 2008;64(Suppl 2):S111-21; Erratum in: Ann Neurol. 2009;65:232
   PubMedGoogle Scholar
• Marek K, Jennings D. Can we image premotor Parkinson disease? Neurology 2009;72(7 Suppl):S21-6; Review
   PubMedGoogle Scholar
• Goldstein DS, Holmes C, Bentho O, Biomarkers to detect central dopamine deficiency and distinguish Parkinson disease from multiple system atrophy. Parkinsonism Relat Disord 2008;14:600-7
   PubMed Web of Science ®Google Scholar
• Haehner A, Hummel T, Hummel C, Olfactory loss may be a first sign of idiopathic Parkinson's disease. Mov Disord 2007;22:839-42
   PubMed Web of Science ®Google Scholar
• Ross GW, Petrovitch H, Abbott RD, Association of olfactory dysfunction with risk for future Parkinson's disease. Ann Neurol 2008;63(2):167-73
   PubMed Web of Science ®Google Scholar
• Siderowf A, Jennings D, Eberly S, Impaired olfaction and other prodromal features in the Parkinson At-Risk Syndrome Study. Mov Disord 2012;27:406-12
   PubMed Web of Science ®Google Scholar
• Wenning GK, Shephard B, Hawkes C, Olfactory function in atypical parkinsonian syndromes. Acta Neurol Scand 1995;91:247-50
   PubMed Web of Science ®Google Scholar
• Doty RL, Singh A, Tetrud J, Langston JW. Lack of major olfactory dysfunction in MPTP-induced parkinsonism. Ann Neurol 1992;32:97-100
   PubMed Web of Science ®Google Scholar
• Millar Vernetti P, Perez Lloret S, Rossi M, Validation of a new scale to assess olfactory dysfunction in patients with Parkinson's disease. Parkinsonism Relat Disord 2012;18:358-61
   PubMed Web of Science ®Google Scholar
• Hummel T, Sekinger B, Wolf SR, 'Sniffin' sticks': olfactory performance assessed by the combined testing of odor identification, odor discrimination and olfactory threshold. Chem Senses 1997;22:39-52
   PubMed Web of Science ®Google Scholar
• Khan NL, Katzenschlager R, Watt H, Olfaction differentiates parkin disease from early-onset parkinsonism and Parkinson disease. Neurology 2004;62:1224-6
   PubMed Web of Science ®Google Scholar
• Baba T, Kikuchi A, Hirayama K, Severe olfactory dysfunction is a prodromal symptom of dementia associated with Parkinson's disease: a 3 year longitudinal study. Brain 2012;135:161-9
   PubMed Web of Science ®Google Scholar
• Postuma RB, Gagnon JF, Vendette M, Quantifying the risk of neurodegenerative disease in idiopathic REM sleep behavior disorder. Neurology 2009;72:1296-300
   PubMed Web of Science ®Google Scholar
• Evatt ML, Chaudhuri KR, Chou KL, Dysautonomia rating scales in Parkinson's disease: sialorrhea, dysphagia, and constipation–critique and recommendations by movement disorders task force on rating scales for Parkinson's disease. Mov Disord 2009;24:635-46
   PubMed Web of Science ®Google Scholar
• Mostile G, Jankovic J. Treatment of dysautonomia associated with Parkinson's disease. Parkinsonism Relat Disord 2009;15(Suppl 3):S224-32
   PubMed Web of Science ®Google Scholar
• Goldstein DS, Sewell L, Sharabi Y. Autonomic dysfunction in PD: a window to early detection? J Neurol Sci 2011;310:118-22
   PubMed Web of Science ®Google Scholar
• Bloch A, Probst A, Bissig H, Alpha-synuclein pathology of the spinal and peripheral autonomic nervous system in neurologically unimpaired elderly subjects. Neuropathol Appl Neurobiol 2006;32:284-95
   PubMed Web of Science ®Google Scholar
• Iwanaga K, Wakabayashi K, Yoshimoto M, Lewy body-type degeneration in cardiac plexus in Parkinson's and incidental Lewy body diseases. Neurology 1999;52:1269-71
   PubMed Web of Science ®Google Scholar
• Devos D, Kroumova M, Bordet R, Heart rate variability and Parkinson's disease severity. J Neural Transm 2003;110:997-1011
   PubMed Web of Science ®Google Scholar
• Kallio M, Haapaniemi T, Turkka J, Heart rate variability in patients with untreated Parkinson's disease. Eur J Neurol 2000;7:667-72
   PubMed Web of Science ®Google Scholar
• Valappil RA, Black JE, Broderick MJ, Exploring the electrocardiogram as a potential tool to screen for premotor Parkinson's disease. Mov Disord 2010;25:2296-303
   PubMed Web of Science ®Google Scholar
• Postuma RB, Lanfranchi PA, Blais H, Cardiac autonomic dysfunction in idiopathic REM sleep behavior disorder. Mov Disord 2010;25:2304-10
   PubMed Web of Science ®Google Scholar
• Crawford T, Goodrich S, Henderson L, Kennard C. Predictive responses in Parkinson's disease: manual keypresses and saccadic eye movements to regular stimulus events. J Neurol Neurosurg Psychiatry 1989;52:1033-42
   PubMed Web of Science ®Google Scholar
• Lueck CJ, Tanyeri S, Crawford TJ, Antisaccades and remembered saccades in Parkinson's disease. J Neurol Neurosurg Psychiatry 1990;53:284-8
   PubMed Web of Science ®Google Scholar
• Vermersch AI, Rivaud S, Vidailhet M, Sequences of memory-guided saccades in Parkinson's disease. Ann Neurol 1994;35:487-90
   PubMed Web of Science ®Google Scholar
• MacAskill MR, Anderson TJ, Jones RD. Adaptive modification of saccade amplitude in Parkinson's disease. Brain 2002;125:1570-82
   PubMed Web of Science ®Google Scholar
• Kimmig H, Haussmann K, Mergner T, Lucking CH. What is pathological with gaze shift fragmentation in Parkinson's disease? J Neurol 2002;249:683-92
   PubMed Web of Science ®Google Scholar
• Blekher T, Weaver M, Rupp J, Multiple step pattern as a biomarker in Parkinson disease. Parkinsonism Relat Disord 2009;15(7):506-10
   PubMed Web of Science ®Google Scholar
• Stoessl AJ, Martin WW, McKeown MJ, Sossi V. Advances in imaging in Parkinson's disease. Lancet Neurol 2011;10:987-1001
   PubMed Web of Science ®Google Scholar
• Cummings JL, Henchcliffe C, Schaier S, The role of dopaminergic imaging in patients with symptoms of dopaminergic system neurodegeneration. Brain 2011;134:3146-66
   PubMed Web of Science ®Google Scholar
• Bohnen NI, Albin RL, Koeppe RA, Positron emission tomography of monoaminergic vesicular binding in aging and Parkinson disease. J Cereb Blood Flow Metab 2006;26:1198-212
   PubMed Web of Science ®Google Scholar
• Dentresangle C, Veyre L, Le Bars D, Striatal D2 dopamine receptor status in Parkinson's disease: an [18F]dopa and [11C]raclopride PET study. Mov Disord 1999;14:1025-30
   PubMed Web of Science ®Google Scholar
• Brooks DJ. PET studies on the early and differential diagnosis of Parkinson's disease. Neurology 1993;43(12 Suppl 6):S6-16
   PubMed Web of Science ®Google Scholar
• Sawle GV. The detection of preclinical Parkinson's disease: what is the role of positron emission tomography? Mov Disord 1993;8:271-7
   PubMed Web of Science ®Google Scholar
• Eidelberg D. Brain networks and clinical penetrance: lessons from hyperkinetic movement disorders. Curr Opin Neurol 2003;16:471-4
   PubMed Web of Science ®Google Scholar
• Eidelberg D. The assessment of neurological systems with functional imaging. Brain Lang 2007;102:192-9
   PubMed Web of Science ®Google Scholar
• Eidelberg D. Metabolic brain networks in neurodegenerative disorders: a functional imaging approach. Trends Neurosci 2009;32:548-57
   PubMed Web of Science ®Google Scholar
• Poston KL, Eidelberg D. Network biomarkers for the diagnosis and treatment of movement disorders. Neurobiol Dis 2009;35:141-7
   PubMed Web of Science ®Google Scholar
• Poston KL, Eidelberg D. FDG PET in the evaluation of Parkinson's disease. PET Clin 2010;5:55-64
   PubMedGoogle Scholar
• Poston KL, Eidelberg D. Functional brain networks and abnormal connectivity in the movement disorders. Neuroimage 2012;62:2261-70
   PubMed Web of Science ®Google Scholar
• Fukuda M, Edwards C, Eidelberg D. Functional brain networks in Parkinson's disease. Parkinsonism Relat Disord 2001;8:91-4
   PubMed Web of Science ®Google Scholar
• Lozza C, Baron JC, Eidelberg D, Executive processes in Parkinson's disease: FDG-PET and network analysis. Hum Brain Mapp 2004;22:236-45
   PubMed Web of Science ®Google Scholar
• Booij J, Knol RJ. SPECT imaging of the dopaminergic system in (premotor) Parkinson's disease. Parkinsonism Relat Disord 2007;13(Suppl 3):S425-8
   PubMedGoogle Scholar
• Waragai M, Yamada T, Matsuda H. Evaluation of brain perfusion SPECT using an easy Z-score imaging system (eZIS) as an adjunct to early-diagnosis of neurodegenerative diseases. J Neurol Sci 2007;260:57-64
   PubMed Web of Science ®Google Scholar
• Orimo S, Ozawa E, Nakade S, (123)I-metaiodobenzylguanidine myocardial scintigraphy in Parkinson's disease. J Neurol Neurosurg Psychiatry 1999;67:189-94
   PubMed Web of Science ®Google Scholar
• Spiegel J. Diagnostic and pathophysiological impact of myocardial MIBG scintigraphy in Parkinson's disease. Parkinsons Dis 2010;2010:p. 295346
   Google Scholar
• Zecca L, Berg D, Arzberger T, In vivo detection of iron and neuromelanin by transcranial sonography: a new approach for early detection of substantia nigra damage. Mov Disord 2005;20:1278-85
   PubMed Web of Science ®Google Scholar
• Berg D, Godau J, Walter U. Transcranial sonography in movement disorders. Lancet Neurol 2008;7:1044-55
   PubMed Web of Science ®Google Scholar
• Martin WR, Wieler M, Gee M. Midbrain iron content in early Parkinson disease: a potential biomarker of disease status. Neurology 2008;70:1411-17
   PubMed Web of Science ®Google Scholar
• Vaillancourt DE, Spraker MB, Prodoehl J, High-resolution diffusion tensor imaging in the substantia nigra of de novo Parkinson disease. Neurology 2009;72:1378-84. Erratum in: Neurology. 2009;72:2059
   PubMed Web of Science ®Google Scholar
• Kwon DH, Kim JM, Oh SH, Seven-Tesla magnetic resonance images of the substantia nigra in Parkinson disease. Ann Neurol 2012;71:267-77
   PubMed Web of Science ®Google Scholar
• Nicoletti G, Lodi R, Condino F, Apparent diffusion coefficient measurements of the middle cerebellar peduncle differentiate the Parkinson variant of MSA from Parkinson's disease and progressive supranuclear palsy. Brain 2006;129:2679-87
   PubMed Web of Science ®Google Scholar
• Schocke MF, Seppi K, Esterhammer R, Diffusion-weighted MRI differentiates the Parkinson variant of multiple systematrophy from PD. Neurology 2002;58:575-80
   PubMed Web of Science ®Google Scholar
• Paviour DC, Thornton JS, Lees AJ, Jager HR. Diffusion-weighted magnetic resonance imaging differentiates Parkinsonian variant of multiple-system atrophy from progressive supranuclear palsy. Mov Disord 2007;22(1):68-74
   PubMed Web of Science ®Google Scholar
• Samii A, Nutt JG, Ransom BR. Parkinson's disease. Lancet 2004;363:1783-93
   PubMed Web of Science ®Google Scholar
• Davie CA. A review of Parkinson's disease. Br Med Bull 2008;86:109-27
   PubMed Web of Science ®Google Scholar
• Lesage S, Brice A. Parkinson's disease: from monogenic forms to genetic susceptibility factors. Hum Mol Genet 2009;18(R1):R48-59
   PubMed Web of Science ®Google Scholar
• International Parkinson Disease Genomics Consortium. Nalls MA, Plagnol V, Hernandez DG, Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies. Lancet 2011;377(9766):641-9
   PubMed Web of Science ®Google Scholar
• Singleton AB, Farrer M, Johnson J, Alpha-synuclein locus triplication causes Parkinson's disease. Science 2003;302(5646):841
   PubMed Web of Science ®Google Scholar
• Funayama M, Hasegawa K, Kowa H, A new locus for Parkinson's disease (PARK8) maps to chromosome 12p11.2-q13.1. Ann Neurol 2002;51:296-301
   PubMed Web of Science ®Google Scholar
• Brice A. Genetics of Parkinson's disease: LRRK2 on the rise. Brain 2005;128:2760-2
   PubMed Web of Science ®Google Scholar
• Kachergus J, Mata IF, Hulihan M, Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations. Am J Hum Genet 2005;76:672-80
   PubMed Web of Science ®Google Scholar
• Anheim M, Elbaz A, Lesage S, Penetrance of Parkinson disease in glucocerebrosidase gene mutation carriers. Neurology 2012;78(6):417-20
   PubMed Web of Science ®Google Scholar
• Wilkins EJ, Rubio JP, Kotschet KE, A DNA resequencing array for genes involved in Parkinson's disease. Parkinsonism Relat Disord 2012;18:386-90
   PubMed Web of Science ®Google Scholar
• Waragai M, Sekiyama K, Sekigawa A, alpha-synuclein and DJ-1 as potential biological fluid biomarkers for Parkinson's disease. Int J Mol Sci 2010;11(11):4257-66
   PubMed Web of Science ®Google Scholar
• Mollenhauer B, Locascio JJ, Schulz-Schaeffer W, alpha-synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurol 2011;10(3):230-40
   PubMed Web of Science ®Google Scholar
• Hong Z, Shi M, Chung KA, DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain 2010;133(Pt 3):713-26
   PubMed Web of Science ®Google Scholar
• Yanamandra K, Gruden MA, Casaite V, alpha-synuclein reactive antibodies as diagnostic biomarkers in blood sera of Parkinson's disease patients. PLoS One 2011;6(4):e18513
   PubMed Web of Science ®Google Scholar
• Lehnert S, Jesse S, Rist W, iTRAQ and multiple reaction monitoring as proteomic tools for biomarker search in cerebrospinal fluid of patients with Parkinson's disease dementia. Exp Neurol 2012;234(2):499-505
   PubMed Web of Science ®Google Scholar
• Anderson L, Hunter CL. Quantitative mass spectrometric multiple reaction monitoring assays for major plasma proteins. Mol Cell Proteomics 2006;5:573-88
   PubMed Web of Science ®Google Scholar
• Wolf-Yadlin A, Hautaniemi S, Lauffenburger DA, White FM. Multiple reaction monitoring for robust quantitative proteomic analysis of cellular signaling networks. Proc Natl Acad Sci USA 2007;104:5860-5
   PubMed Web of Science ®Google Scholar
• Ishigami N, Tokuda T, Ikegawa M, Cerebrospinal fluid proteomic patterns discriminate Parkinson's disease and multiple system atrophy. Mov Disord 2012;27:851-7
   PubMed Web of Science ®Google Scholar
• Cassani E, Cancello R, Cavanna F, Serum adiponectin levels in advanced-stage Parkinson's disease patients. Parkinsons Dis 2011;2011:624764
   PubMedGoogle Scholar
• Kitada T, Asakawa S, Hattori N, Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 1998;392:605-8
   PubMed Web of Science ®Google Scholar
• Lohmann E, Periquet M, Bonifati V, How much phenotypic variation can be attributed to parkin genotype? Ann Neurol 2003;54:176-85
   PubMed Web of Science ®Google Scholar
• Valente EM, Salvi S, Ialongo T, PINK1 mutations are associated with sporadic early-onset parkinsonism. Ann Neurol 2004;56:336-441
   PubMed Web of Science ®Google Scholar
• Bonifati V, Rizzu P, van Baren MJ, Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 2003;299:256-9
   PubMed Web of Science ®Google Scholar
• Ramirez A, Heimbach A, Grundemann J, Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. Nat Genet 2006;38:1184-91
   PubMed Web of Science ®Google Scholar
• Strauss KM, Martins LM, Plun-Favreau H, Loss of function mutations in the gene encoding Omi/HtrA2 in Parkinson's disease. Hum Mol Genet 2005;14:2099-11
   PubMed Web of Science ®Google Scholar